Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants

Thrombosis Journal

Carsten Perka¹ 

[1] Orthopaedic Department, Charité, University Medicine Berlin, Free and Humboldt-University of Berlin, Berlin, Germany

关键词: Apixaban;    Rivaroxaban;    Dabigatran etexilate;    Anticoagulation;    Knee replacement surgery;    Hip replacement surgery;    Thromboprophylaxis;   

Others  :  839006
DOI  :  10.1186/1477-9560-9-17

 received in 2011-06-06, accepted in 2011-11-16,  发布年份 2011

【 摘 要 】

In European countries, low-molecular-weight heparin is generally initiated preoperatively for thromboprophylaxis in hip or knee replacement surgery. The objective of this review is to compare pre- and postoperative thromboprophylaxis strategies using available evidence, and discuss the challenges and issues that arise. Surgery is the first step in the process of thrombus formation, but thrombosis is not an instant process and the formation and growth of the thrombus can take several days or weeks. Hence, it may be possible to stop this process if thromboprophylaxis is initiated after surgery. Meta-analyses or systematic reviews comparing pre- and postoperative initiation of therapy have found no consistent differences in efficacy and similar safety (bleeding rates) between the two strategies. The recently available oral anticoagulant dabigatran etexilate provides thromboprophylaxis when administered postoperatively and is as safe as preoperative enoxaparin. Further support for the use of postoperative oral thromboprophylaxis in hip or knee replacement surgery has been provided by the phase III clinical trials of rivaroxaban and apixaban versus preoperative enoxaparin. Postoperative thromboprophylaxis offers the opportunity to change management practices in Europe. As postoperative initiation may have a clinical benefit in some settings (e.g. for neuraxial anesthesia) and practical advantages (e.g. allowing same-day admission), it is a worthwhile thromboprophylactic strategy for hip or knee replacement surgery.

【 授权许可】

   
2011 Perka; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 8th edition. 2008, 133:381S-453S.
• [2]Nicolaides AN, Fareed J, Kakkar AK, Breddin HK, Goldhaber SZ, Hull R, Kakkar VV, Michiels JJ, Myers K, Samama M, Sasahara A, Kalodiki E: Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006, 25:101-161.
• [3]Hull RD, Pineo GF, MacIsaac S: Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 2001, 101:V155-V162.
• [4]Sharnoff JG, DeBlasio G: Prevention of fatal postoperative thromboembolism by heparin prophylaxis. Lancet 1970, 2:1006-1007.
• [5]Strebel N, Prins M, Agnelli G, Buller HR: Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002, 162:1451-1456.
• [6]Gallus AS, Hirsh J, Tutle RJ, Trebilcock R, O'Brien SE, Carroll JJ, Minden JH, Hudecki SM: Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973, 288:545-551.
• [7]Dahl OE, Aspelin T, Lyberg T: The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coagul Fibrinolysis 1995, 6:709-717.
• [8]Bjørnarå BT, Gudmundsen TE, Dahl OE: Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006, 88:386-391.
• [9]Dahl OE, Gudmundsen TE, Haukeland L: Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000, 71:47-50.
• [10]Arcelus JI, Monreal M, Caprini JA, Guisado JG, Soto MJ, Nunez MJ, Alvarez JC: Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost 2008, 99:546-551.
• [11]Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr: Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003, 124(6 Suppl):349S-356S.
• [12]Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R: Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199-2207.
• [13]Warwick D, Rosencher N: The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost 2010, 16:394-405.
• [14]Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL, Heit JA, Mulroy MF, Rosenquist RW, Tryba M, Yuan CS: Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines. Reg Anesth Pain Med Third edition. 2010, 35:64-101.
• [15]Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM: Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 2005, 3:2006-2014.
• [16]Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF: Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000, 20:771-775.
• [17]Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, Vernier I, Boneu B: Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991, 63:385-390.
• [18]Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX: Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002, 105:225-231.
• [19]Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185. 20
• [20]Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
• [21]Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ: Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105:721-729.
• [22]Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
• [23]Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39. 24
• [24]Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
• [25]Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
• [26]Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM: Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
• [27]Kinlough-Rathbone RL, Packham MA, Mustard JF: Vessel injury, platelet adherence, and platelet survival. Arteriosclerosis 1983, 3:529-546.
• [28]Joist JH: Hypercoagulability: introduction and perspective. Semin Thromb Hemost 1990, 16:151-157.
• [29]Bullingham A, Strunin L: Prevention of postoperative venous thromboembolism. Br J Anaesth 1995, 75:622-630.
• [30]Cohen AT: Applying risk assessment models in orthopaedic surgery: effective risk stratification. Blood Coagul Fibrinolysis 1990, 10(Suppl 2):S63-S70.
• [31]Zaw HM, Osborne IC, Pettit PN, Cohen AT: Risk factors for venous thromboembolism in orthopedic surgery. Isr Med Assoc J 2002, 4:1040-1042.
• [32]White RH, Romano PS, Zhou H, Rodrigo J, Bargar W: Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998, 158:1525-1531.
• [33]Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L: Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991, 303:1431-1435.
• [34]Samama CM, Ravaud P, Parent F, Barre J, Mertl P, Mismetti P: Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007, 5:2360-2367.
• [35]Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J: Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007, 5:1438-1443.
• [36]Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y: Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996, 27:224-228.
• [37]Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996, 335:696-700.
• [38]Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H: Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997, 77:26-31.
• [39]Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G, Petersen AO, Siem P, Hørlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Møller JC, Rotwitt L, Christensen F, Nielsen JB, Jørgensen PS, Paaske B, Tørholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E, et al.: Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998, 89:281-287.
• [40]Yamaguchi T, Hasegawa M, Niimi R, Sudo A: Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thromb Res 2010, 126:e323-e326.
• [41]Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Dutheil JJ, Vielpeau C, PROTHEGE study group, GETHCAM study group: Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thromb Res 2010, 126:e298-e304.
• [42]Wells PS, Borah BJ, Sengupta N, Supina D, McDonald HP, Kwong LM: Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care 2010, 16:857-863.
• [43]Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G: Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986, 73:204-208.
• [44]Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyak K, Francis CW, Marder VJ, Raskob GE: Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001, 161:1952-1960.
• [45]Sanofi-Aventis U.S.LLC: Lovenox Prescribing Information. [http://products.sanofi-aventis.us/lovenox/lovenox.html] webcite 2008.
• [46]Kearon C, Hirsh J: Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995, 155:366-372.
• [47]Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:338S-400S.
• [48]Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M: A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929.
• [49]Raskob GE, Hirsh J: Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003, 124:379S-385S.
• [50]Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA: Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999, 159:137-141.
• [51]Dahl OE: Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement: rationale for dose regimen. Clin Appl Thromb Hemost 2009, 15(Suppl):17S-24S.
• [52]EMEA: Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. [http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf] webcite CPMP/EWP/707/98 Rev.1. 2007. European Agency for the Evaluation of Medicinal Products
• [53]Bayer: Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program. [http:/ / www.orthogate.org/ news/ industry-news/ xarelto-reduces-symptomatic-vte.htm l] webciteBayer Press Release; 2008.
• [54]Huisman MV, Quinlan DJ, Dahl OE, Schulman S: Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010, 3:652-660.
• [55]Dahl OE, Kurth AA, Rosencher N, Schnee JM, Clemens A, Hantel S, Eriksson BI: Delay in initiating prophylactic treatment with dabigatran etexilate following total hip or knee replacement surgery did not affect efficacy. Pooled analysis of two European phase III trials. J Thromb Haemost 2009, 7(Suppl 2):695.